Dec 23, 2024 · BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.

Mission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.. Vision. Transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world.

2 DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 3 Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China.

BeiGene seeks to develop and deliver impactful medicines to more patients around the world. The products shown here may not be available in all countries or regions. Please visit your local country website for local information.

Clare Fisher joined BeiGene in 2021 as Senior Vice President, Business Development and Mergers & Acquisitions (ex-China), bringing more than two decades of healthcare experience in leadership roles including corporate and business development, M&A, and strategy.

In 2023, BeiGene laid the foundation to become a leader in global health equity. We developed a vision and mission for this commitment that reflects the voices and needs of at-risk patients, and defined what “global health equity” means to BeiGene as a company.

BeiGene is a publicly traded global oncology company. BeiGene had its IPO on the NASDAQ in February 2016, and is currently traded on the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange.

The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, harnessing the body’s immune system to attack tumors, and targeting specific biomarkers of cancer. The tilted angle of the button embodies our path which is not always straight-forward …

Jul 23, 2024 · BeiGene’s $800 million investment is the culmination of a three-year project to expand the Company’s integrated manufacturing and research and development footprint in the U.S. BeiGene will create hundreds of skilled high-tech jobs at the site by the end of 2025.

Lot 4-401 & 4-402, Level 4, The Starling Mall No, 6, Jalan SS 21/37, Damansara Utama, 47400 Petaling Jaya, Selangor, Malaysia